Clinical Trials Logo

Infections clinical trials

View clinical trials related to Infections.

Filter by:

NCT ID: NCT05256303 Completed - Asthma Clinical Trials

Rural Hospital-Level Care at Home for Acutely Ill Adults

Start date: February 16, 2022
Phase: N/A
Study type: Interventional

This study examines the implications of providing hospital-level care in rural homes.

NCT ID: NCT05255185 Completed - Infection Clinical Trials

"Domino" Therapy Treat the Infection Around the Prosthesis After the Limb Salvage Surgery of Bone Tumor

Start date: August 1, 2017
Phase: N/A
Study type: Interventional

Tumor resection and prosthetic replacement have become the treatments of choice for malignant bone tumors. Infections are the main cause of failure of limb salvage surgeries. Therefore, treatment of infections around prostheses after limb salvage is important, but is also challenging. Our research team designed a "domino" sequential treatment plan to treat postoperative infections around tumor prostheses and evaluated its efficacy.

NCT ID: NCT05254990 Recruiting - Severe COVID-19 Clinical Trials

Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

Start date: April 6, 2022
Phase: Phase 3
Study type: Interventional

Primary objective: - To evaluate the efficacy of oral reparixin versus standard care alone in limiting disease progression in adult patients hospitalised for infectious pneumonia acquired in the community (CAP), including COVID-19. Secondary objectives: - To determine the effect of reparixin on several disease severity/progression measures including recovery, ventilatory free days and mortality. Safety objectives: - To evaluate the safety of oral reparixin versus placebo in the specific clinical setting.

NCT ID: NCT05254522 Recruiting - Clinical trials for Fever of Unknown Origin

Fever of Unknown Orgin Registry in Internal Medicine Unit and Infectious Disease Units

FUO
Start date: September 19, 2019
Phase:
Study type: Observational [Patient Registry]

This registry has the aim to collect epidemiological and clinical data of classical FUO cases in Italian Internal medicine Dept. and in Italian Infection diseases Dept.

NCT ID: NCT05252468 Completed - COVID-19 Clinical Trials

COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID-19).

Start date: May 19, 2021
Phase: N/A
Study type: Interventional

TAFFIX is a nasal powder spray that immediately creates a protective acidic barrier on the nasal mucosa against infection by inhaled viruses. The protective barrier lasts 5 hours. TAFFIX is approved as a medical device in Israel, intended for use to block inhaled viruses within the nasal cavity. In Europe, it is registered as a medical device indicated for use as a protective mechanical barrier against allergens and viruses (e.g., SARS-CoV-2) within the nasal cavity. TAFFIX is used as additional safety mean together with masks, hygiene, and social distancing. The study rationale is to evaluate whether daily use of TaffiX™ as prophylaxis will reduce the rate of SARS- CoV-2 infection and other upper respiratory infections, compared to the placebo control rate.

NCT ID: NCT05251584 Recruiting - Clinical trials for Peritoneal Dialysis-related Infection

Effects of Topical Gentamicin on the Prevention of Peritoneal Dialysis Related Infection

Start date: December 1, 2021
Phase: N/A
Study type: Interventional

Peritoneal dialysis-related infection is a complication that leads to peritoneal dialysis catheter removal or patient death. The present study aimed to investigate peritoneal dialysis-related infection, causative pathogens resulting in topical 2% mupirocin ointments period compare with 0.1% gentamicin cream period. Rate of catheter removal, time to first peritoneal dialysis-related infection after apply gentamicin cream.

NCT ID: NCT05250050 Recruiting - Clinical trials for Helicobacter Pylori Infection

Susceptibility-Guided Therapy for Helicobacter Pylori Infection Treatment

Start date: March 25, 2022
Phase: Phase 4
Study type: Interventional

This multicenter randomized controlled clinical trial was conducted to compare the eradication efficacy and health economic benefits of individualized regimens based on HP drug resistance mutation gene detection (multiple PCR method), individualized regimens based on HP traditional drug sensitivity testing (E-test method) and empirical regimens in the Helicobacter pylori treatment.

NCT ID: NCT05248490 Completed - Clinical trials for Bone and Joint Infection

Impact of Pharmaceutical Interviews Regarding the Management of Adverse Effects Related to the Antibiotic Therapy Used to Treat Osteoarticular Infections During Return Home

EFIRAD
Start date: March 22, 2022
Phase: N/A
Study type: Interventional

The primary objective is to evaluate the impact of Pharmaceutical Interviews in the patient self-management of non-severe side effects caused by antibiotics prescribed for the treatment of osteoarticular infections when the patient returns home.

NCT ID: NCT05247281 Enrolling by invitation - Clinical trials for Prosthetic Joint Infection

NGS vs Culture Outcomes for Treatment of PJI

Start date: September 21, 2022
Phase: N/A
Study type: Interventional

This multicenter, randomized controlled trial will compare the use of NGS and traditional culture in directing antimicrobial treatment for patients with periprosthetic joint infection.

NCT ID: NCT05247112 Recruiting - Clinical trials for Helicobacter Pylori Infection

Prevalence and Trends of Antimicrobial Resistance of Helicobacter Pylori in Korea

Start date: July 1, 2003
Phase:
Study type: Observational

To assess antimicrobial resistance rates and minimal inhibitory concentrations in H. pylori isolated from patients with upper gastrointestinal disease with long-term period.